Abstract
Cardiac hypertrophy/remodeling manifests as a critical condition which may likely predispose to the risk of fatal heart failure and multiple organ dysfunction if not efficiently addressed, as a result of irreversible neuroendocrine, autonomic and immune system imbalances. Undeniably, the over-excitation of sympathetic and/or the breakdown of central parasympathetic tone play a significant role to be the basis of the persistent immune activation in chronic heart failure (CHF) which, to a certain extent, is primed by inflammatory reactions in the Central Nervous System. Moreover, till today, the clinical management of CHF seeks the identification of molecularly targeted drugs in comparison to those considered so far. This review focuses on the possible neuroimmune-mediated pathways involved in CHF and throws light on the current therapeutic strategies.
Keywords: Autonomic system, chronic heart failure, inflammatory mediators.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Neuroimmune Activation in Chronic Heart Failure
Volume: 13 Issue: 1
Author(s): Giorgio Fiore, Patrizia Suppress, Vincenzo Triggiani, Francesco Resta and Carlo Sabba
Affiliation:
Keywords: Autonomic system, chronic heart failure, inflammatory mediators.
Abstract: Cardiac hypertrophy/remodeling manifests as a critical condition which may likely predispose to the risk of fatal heart failure and multiple organ dysfunction if not efficiently addressed, as a result of irreversible neuroendocrine, autonomic and immune system imbalances. Undeniably, the over-excitation of sympathetic and/or the breakdown of central parasympathetic tone play a significant role to be the basis of the persistent immune activation in chronic heart failure (CHF) which, to a certain extent, is primed by inflammatory reactions in the Central Nervous System. Moreover, till today, the clinical management of CHF seeks the identification of molecularly targeted drugs in comparison to those considered so far. This review focuses on the possible neuroimmune-mediated pathways involved in CHF and throws light on the current therapeutic strategies.
Export Options
About this article
Cite this article as:
Fiore Giorgio, Suppress Patrizia, Triggiani Vincenzo, Resta Francesco and Sabba Carlo, Neuroimmune Activation in Chronic Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010009
DOI https://dx.doi.org/10.2174/1871530311313010009 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Renin-Angiotensin System and Alzheimer’s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives
Protein & Peptide Letters Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review
Current Genomics The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Pharmacogenetics of Drug Transporters
Current Pharmaceutical Design Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer
Current Cancer Drug Targets Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews The Long-Term Effect of Medically Enhancing Melanin Intrinsic Bioenergetics Capacity in Prematurity
Current Genomics Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress- Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways
Current Neurovascular Research Improvement in Quality of Life in Old People with Aortic Stenosis after Transcatheter Aortic Valve Implantation
Current Signal Transduction Therapy Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Left Ventricular 2-[<sup>18</sup>F]-Fluoro-2-Deoxy-D-Glucose Uptake Using Modified Oral Glucose Loading Protocol With Pre-Medicated Niacin On Positron Emission Tomography/Computed Tomography - A Preliminary Study
Current Molecular Imaging (Discontinued)